FLAVONE, 3,3',4',5,7-PENTAHYDROXY-
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Charles Drew University of Medicine and ScienceSmall moleculePhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 73/ 100
Competitive context
229 Active assets in the Metastatic Castration-resistant Prostate Cancer (mCRPC) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Darolutamide Bayer | Phase 4 | BBB |
Enzalutamide Prostate Cancer Clinical Trials Consortium | Phase 4 | BBB |
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Ding-Wei Ye | Phase 4 | BBB |
Darolutamide Bayer | Phase 3 | BB |
RADIUM RA-223 University of California, San Francisco | Phase 4 | BB |
View all 50 →
Same molecule, other indications
FLAVONE, 3,3',4',5,7-PENTAHYDROXY- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →